BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Laterza R, Schirinzi A, Bruno R, Genco R, Contino R, Ostuni A, Di Serio F. SARS-CoV-2 antibodies: Comparison of three high-throughput immunoassays versus the neutralization test. Eur J Clin Invest 2021;51:e13573. [PMID: 33870493 DOI: 10.1111/eci.13573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Bonifacio MA, Laterza R, Vinella A, Schirinzi A, Defilippis M, Di Serio F, Ostuni A, Fasanella A, Mariggiò MA. Correlation between In Vitro Neutralization Assay and Serological Tests for Protective Antibodies Detection. IJMS 2022;23:9566. [DOI: 10.3390/ijms23179566] [Reference Citation Analysis]
2 Lichtenegger S, Saiger S, Hardt M, Kulnik S, Wagner GE, Kleinhappl B, Assig K, Zauner A, Ober M, Kimpel J, von Laer D, Zatloukal K, Steinmetz I. Development of a Rapid Live SARS-CoV-2 Neutralization Assay Based on a qPCR Readout. J Clin Microbiol 2022;:e0037622. [PMID: 35642515 DOI: 10.1128/jcm.00376-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Terao T, Yamashita T, Fukumoto A, Kamura Y, Ikeda D, Kuzume A, Tabata R, Tsushima T, Miura D, Narita K, Takeuchi M, Doi M, Umezawa Y, Otsuka Y, Takamatsu H, Matsue K. Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma. Int J Hematol 2022. [PMID: 35190963 DOI: 10.1007/s12185-022-03300-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Firinu D, Perra A, Campagna M, Littera R, Meloni F, Sedda F, Conti M, Costanzo G, Erbi M, Usai G, Locci C, Carta MG, Cappai R, Orrù G, Del Giacco S, Coghe F, Chessa L. Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study. Vaccines (Basel) 2021;9:1478. [PMID: 34960224 DOI: 10.3390/vaccines9121478] [Reference Citation Analysis]
5 Firinu D, Perra A, Campagna M, Littera R, Meloni F, Sedda F, Conti M, Costanzo G, Erbi M, Usai G, Locci C, Carta MG, Cappai R, Orrù G, Del Giacco S, Coghe F, Chessa L. Evaluation of Antibody Response to Heterologous Prime-Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study. Vaccines (Basel) 2021;9:1478. [PMID: 34960224 DOI: 10.3390/vaccines9121478] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Dekervel M, Henry N, Torreggiani M, Pouteau LM, Imiela JP, Mellaza C, Garnier AS, Dujardin A, Asfar M, Ducancelle A, Paquin A, Blanchi S, Besson V, Piccoli GB, Augusto JF. Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis. Clin Kidney J 2021;14:2349-55. [PMID: 34754430 DOI: 10.1093/ckj/sfab152] [Cited by in Crossref: 6] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
7 Gallichotte EN, Nehring M, Young MC, Pugh S, Sexton NR, Fitzmeyer E, Quicke KM, Richardson M, Pabilonia KL, Ehrhart N, Fosdick BK, VandeWoude S, Ebel GD. Durable Antibody Responses in Staff at Two Long-Term Care Facilities, during and Post SARS-CoV-2 Outbreaks. Microbiol Spectr 2021;9:e0022421. [PMID: 34287058 DOI: 10.1128/Spectrum.00224-21] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Laterza R, Schirinzi A, Bruno R, Genco R, Contino R, Ostuni A, Di Serio F. SARS-CoV-2 antibodies: Comparison of three high-throughput immunoassays versus the neutralization test. Eur J Clin Invest 2021;51:e13573. [PMID: 33870493 DOI: 10.1111/eci.13573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]